Company's Second Major Acquisition Will Extend Orphan and Rare Disease Research Base and Growth Opportunities ROCKVILLE, Md., May 12, 2021 /PRNewswire/ Emmes, a global, full-service
MONTREAL, May 12, 2021 /CNW/ - The Quebec – Clinical Research Organization in Cancer (Q-CROC) and Colorectal Cancer Canada (CCC) are partnering to endeavour .
/PRNewswire/ Emmes (the "Company"), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and.
Share this article
Share this article
WASHINGTON, May 12, 2021 /PRNewswire/ MCRA, LLC, the leading privately held medical device and biologics advisory firm and Clinical Research Organization (CRO) integrating U.S. and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, Quality Assurance, and Medical Device Cybersecurity, is pleased to announce its role in the successful management and execution of Simplify Medical s two clinical studies and approvals by the U.S. Food and Drug Administration (FDA) for the Simplify Cervical Artificial Disc (Simplify Disc) to be used at one-level and two contiguous levels in the cervical spine.
Abigail Allen, MCRA s Vice President of Clinical Affairs, said, MCRA is honored to have supported Simplify Medical with the approval of their two-level disc just six months after the one-level approval. It has been a true testament to the teamwork and collaboration between the two companies, and all of our sites, to get the
Share this article
Share this article
WILLINGTON, England, May 10, 2021 /PRNewswire/ Bionical Emas, a global specialist Clinical Research Organization (CRO), has today announced the launch of a U.S. Expanded Access Program for Jazz Pharmaceuticals investigational therapy JZP458 (asparaginase
Erwinia chrysanthemi (recombinant)) for the treatment of adult and pediatric patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) following hypersensitivity or silent inactivation to
E. coli-derived asparaginases. JZP458 is currently under FDA review for marketing authorization in the United States. The Expanded Access Program (EAP) provides a mechanism to fulfill unsolicited physician requests in the U.S. and support the special need of a patient.